Primeadine
Primeadine

Video interview: talking senescence with Nina Khera

Teenage founder of Canadian start-up Biotein hunts a universal phenotype for senescent cells.

As we’ve covered in the past, Biotein’s Nina Khera has a mission to play her part of the Longevity science community.

Longevity.Technology: Once you get past the fact that Nina is still so early in her career – she’s still at school – it’s great to learn about her ambitions for the Longevity field and her team’s intention to use AI and machine learning to create senolytic clinical interventions.

First Longevity

As Nina told us earlier: “The research pertaining to senolytics and senescent cells is not advanced enough that we would think the supplements are safe or confirmed to work fully. Senolytics need to have more peer-reviewed studies, and that’s when we would recommend them.”

Nina has some very interesting things to say:

First Longevity

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
Primeadine
lumen
Primeadine
lumen

Latest articles

Senescence: a new weapon in the fight against cancer

Targeting senescent “zombie” cells may improve cancer survival rates. How well women with cervical cancer respond to treatment (and survive) correlates with the level of...

Wearables and AI on the frontline of Longevity

Disruptive platforms are set for huge growth ahead of the inevitable consolidation and acquisitions: the race is on. Rise and fall used to be the...

The time is right for specialist Longevity investment

We speak to the co-founder of LongeVC – an investment firm focused exclusively on Longevity. Earlier this month, LongeVC emerged onto the scene with a...

Would you invest $1000 per week to live longer?

Money can't buy happiness - but it can buy Longevity;  this updated report from UBS identifies that investors are re-thinking where they invest their...